Partnering Opportunities

ViroStatics is developing novel NCEs in the areas of antivirals (including HIV) and oncology. In addition, we have developed innovative biomarker assays of immune system response to immunotherapeutics and vaccines.  We seek to partner with one or more companies to maximize the value of these assets.

Screening for New AV-HALT Compounds
ViroStatics has developed proprietary laboratory methodologies to allow our scientists to screen a large number of candidate compounds for their intrinsic anti-HIV activity, unique immunomodulatory properties, impact upon cell cycle progression, and potential toxicities.  The Company is interested in reaching out to potential in-licensing partners in the oncology and rheumatology spaces to identify the next generation of virostatic AV-HALTs for commercialization to combat HIV/AIDS and other chronic diseases.

Oncology Partnering
ViroStatics has a library of 300+ compounds demonstrating in vivo activity against osteosarcoma, Burkitt's lymphoma, imatinib-resistant (T315I) CML and other tumors.  We seek a partner for development and ultimate commercialization of these assets.

Commercialization of Diagnostic Assays
The Company has developed novel biomarker assays to document beneficial changes in key immunological responses against viral pathogens during therapy.  One such test, an assay for memory T-cells with high proliferative capacity, has demonstrated that increased numbers of these functional T-cells correlates with the immune system's ability to control HV replication.  The test holds promise as a tool to evaluate immunotherapies (such as virostatic AV-HALTs and targeted immune amplification strategies) in the treatment of HIV/AIDS and other chronic diseases. The Company is looking to partner to successfully commercialize our novel diagnostic assays.

For more information please contact Michael Stevens, Chief Development Officer at m.stevens@virostatics.com